QuestionSBA
QuestionChoice
Sitagliptin is a DPP-4 inhibitor, and acts by potentiating GLP-1 resulting in increased insulin release and decreased glucagon release. It is currently recommended as a second-line treatment option for T2DM.
10006870
e
Sitagliptin
QuestionChoice
Exanatide is a GLP-1 agonist, which is currently recommended as a management option for patients in whom triple therapy with metformin and two other drugs has been ineffective. GLP-1 agonists increase insulin release in response to food, and also have the beneficial side effect of weight loss.
10006869
d
Exanatide
QuestionChoice
Gliclazide is a sulphonylurea, which increases the release of insulin from pancreatic B-cells. It increases the risk of hypoglycaemia, and may cause weight gain.
10006867
b
Gliclazide
QuestionChoice
Dapagliflozin is correct. This is an SGLT-2 inhibitor, which prevents glucose reabsorption in the proximal convoluted tubule, resulting in increased urinary glucose excretion. An SGLT-2 inhibitor is the second-line pharmacological option for patients with T2DM with established cardiovascular disease or a high risk of developing cardiovascular disease. SGLT-2 inhibitors can increase the risk of developing urinary tract infections, but can also result in the beneficial side effect of weight loss.
10006866
a
Dapagliflozin
QuestionChoice
Modified-release metformin may be started in patients with type 2 diabetes who experience gastrointestinal side effects with standard-release metformin. It acts via the same mechanism as metformin.
10006868
c
Modified-release metformin
Concept
Chapter
2693
3761
Type 2 Diabetes Mellitus
Topic
133
Endocrinology
13920
A 57-year-old male with poorly controlled type 2 diabetes presents to the diabetes clinic. His HbA1c was recently measured and was found to be raised at 67 mmol/mol. This is only a slight improvement from his last HbA1c measurement which was 70mmol/mol three months previously. He is obese, and is currently taking metformin and atorvastatin. He is started on a new drug which the doctor explains works by increasing glucose excretion in the urine.

Which of the following has most likely been prescribed to the patient?
a